Crossmark

Current Treatment Options for Breast Cancer Brain Metastases

Crossref DOI link: https://doi.org/10.1007/s11864-019-0618-5

Published Online: 2019-02-15

Published Print: 2019-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Raghunath, Arrvind

Desai, Kunal

Ahluwalia, Manmeet S.
License Information

Text and Data Mining valid from 2019-02-15
More Information

Article History

First Online: 15 February 2019

Compliance with Ethical Standards

:

: Arrvind Raghunath declares that he has no conflict of interest. Kunal Desai declares that he has no conflict of interest. Manmeet S. Ahluwalia has received research funding from Incyte, Bristol-Myers Squibb, AstraZeneca, TRACON, Novartis, Novocure, AbbVie, Pharmacyclics, Merck, and Bayer; has received compensation from Incyte, Bristol-Myers Squibb, AstraZeneca, Novocure, Monteris Medical, Caris Life Sciences, MR Solutions, AbbVie, CBT Pharmaceuticals, Flatiron Health, Varian Medical Systems, and MimiVax for service as a consultant; has received compensation from VBI Vaccines for participating on a data and safety monitoring board; and has stock options in MimiVax and Doctible.

: This article does not contain any studies with human or animal subjects performed by any of the authors.